Revenue rebounded to $1.3B in Q3 2026 with a 75.8% gross margin, but the 9.9% operating margin follows multiple quarters of losses, including an operating margin of -126.4% in 2025Q4, suggesting the profit may be an isolated event.
Moderna, Inc. (MRNA) annual income statement — 10-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 |
|---|
| Sales/Revenue | 2.52B | 1.94B | 3.2B | 6.85B | 18.88B | 17.74B | 803.39M | 60.21M | 135.07M | 205.82M | 108.4M |
| Revenue Growth % | 13.69% | -39.23% | -53.29% | -63.72% | 6.42% | 2107.63% | 1234.34% | -55.42% | -34.38% | 89.88% | - |
| Cost of Goods Sold | 1.82B | 868M | 1.46B | 4.69B | 5.42B | 2.62B | 39.18M | 31.02M | 24.86M | 20.54M | 15.11M |
| COGS % of Revenue | - | 44.65% | 45.76% | 68.53% | 28.69% | 14.76% | 4.88% | 51.52% | 18.41% | 9.98% | 13.94% |
| Gross Profit | 707M | 1.08B | 1.74B | 2.15B | 13.46B | 15.12B | 764.21M | 29.19M | 110.21M | 185.29M | 93.28M |
| Gross Margin % | 28% | 55.35% | 54.24% | 31.47% | 71.31% | 85.24% | 95.12% | 48.48% | 81.59% | 90.02% | 86.06% |
| Gross Profit Growth % | - | -37.98% | -19.49% | -83.99% | -10.98% | 1878.38% | 2518.24% | -73.52% | -40.52% | 98.63% | - |
| Operating Expenses | 3.64B | 4.15B | 5.68B | 6.39B | 4.04B | 1.82B | 1.53B | 574.91M | 94.25M | 454.64M | 317.05M |
| OpEx % of Revenue | - | 213.48% | 177.56% | 93.37% | 21.4% | 10.28% | 190.11% | 954.85% | 69.78% | 220.89% | 292.5% |
| Selling, General & Admin | 979M | 1.02B | 1.17B | 1.55B | 1.13B | 567M | 188.27M | 109.62M | 94.25M | 64.72M | 57.45M |
| SG&A % of Revenue | - | 52.37% | 36.7% | 22.62% | 6% | 3.2% | 23.43% | 182.07% | 69.78% | 31.45% | 53% |
| Research & Development | 2.66B | 3.13B | 4.54B | 4.84B | 3.29B | 1.99B | 1.37B | 496.31M | 454.08M | 410.46M | 274.72M |
| R&D % of Revenue | - | 161.11% | 142.01% | 70.75% | 17.46% | 11.23% | 170.57% | 824.31% | 336.19% | 199.42% | 253.44% |
| Other Operating Expenses | 0 | 0 | -37M | 0 | -388M | -735M | -31.25M | -31.02M | -454.08M | -20.54M | -15.11M |
| Operating Income | -2.93B | -3.07B | -3.94B | -4.24B | 9.42B | 13.3B | -763.14M | -545.72M | -468.87M | -269.36M | -223.77M |
| Operating Margin % | -116.04% | -158.13% | -123.32% | -61.9% | 49.91% | 74.97% | -94.99% | -906.38% | -347.13% | -130.87% | -206.44% |
| Operating Income Growth % | - | 22.08% | 6.94% | -145% | -29.15% | 1842.27% | -39.84% | -16.39% | -74.07% | -20.37% | - |
| EBITDA | -2.67B | -2.86B | -3.76B | -3.62B | 9.77B | 13.53B | -732.14M | -514.7M | -444M | -248.82M | -208.66M |
| EBITDA Margin % | -105.86% | -147.07% | -117.41% | -52.83% | 51.75% | 76.27% | -91.13% | -854.85% | -328.73% | -120.89% | -192.5% |
| EBITDA Growth % | 17.88% | 23.88% | -3.81% | -137.04% | -27.79% | 1947.72% | -42.25% | -15.92% | -78.44% | -19.25% | - |
| D&A (Non-Cash Add-back) | 257M | 215M | 189M | 621M | 348M | 232M | 31M | 31.02M | 24.86M | 20.54M | 15.11M |
| EBIT | -2.71B | -2.77B | -3.58B | -3.9B | 9.6B | 13.3B | -734.63M | -508.1M | -436.91M | -255.86M | -223.77M |
| Net Interest Income | 246M | 304M | 401M | 383M | 171M | 0 | 14.83M | 31.92M | 23.93M | 15.1M | 11.31M |
| Interest Income | 271M | 314M | 425M | 421M | 200M | 18M | 24.71M | 38.53M | 27.02M | 15.23M | 11.31M |
| Interest Expense | 25M | 10M | 24M | 38M | 29M | 18M | 9.89M | 6.61M | 3.1M | 132K | 0 |
| Other Income/Expense | 201M | 306M | 338M | 297M | 155M | -11M | 18.63M | 31M | 28.86M | 13.36M | 8.6M |
| Pretax Income | -2.73B | -2.77B | -3.61B | -3.94B | 9.57B | 13.29B | -744.51M | -514.72M | -440.01M | -256M | -215.17M |
| Pretax Margin % | -108.08% | -142.39% | -112.75% | -57.56% | 50.73% | 74.9% | -92.67% | -854.88% | -325.77% | -124.38% | -198.5% |
| Income Tax | 60M | 54M | -46M | 772M | 1.21B | 1.08B | 2.55M | -695K | 326K | -80K | 1.04M |
| Effective Tax Rate % | -2.2% | -1.95% | 1.28% | -19.58% | 12.67% | 8.15% | -0.34% | 0.14% | -0.07% | 0.03% | -0.48% |
| Net Income | -2.79B | -2.82B | -3.56B | -4.71B | 8.36B | 12.2B | -747.06M | -514.02M | -384.73M | -255.92M | -216.21M |
| Net Margin % | -110.46% | -145.16% | -111.32% | -68.84% | 44.3% | 68.8% | -92.99% | -853.73% | -284.84% | -124.34% | -199.46% |
| Net Income Growth % | 10.49% | 20.75% | 24.46% | -156.37% | -31.47% | 1733.33% | -45.34% | -33.6% | -50.34% | -18.36% | - |
| Net Income (Continuing) | -2.79B | -2.82B | -3.56B | -4.71B | 8.36B | 12.2B | -747.06M | -514.02M | -384.73M | -255.92M | -216.21M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -6.49 | -7.26 | -9.27 | -12.34 | 20.10 | 28.29 | -1.96 | -1.55 | -1.17 | -0.72 | -3.79 |
| EPS Growth % | 12.14% | 21.68% | 24.88% | -161.39% | -28.95% | 1543.37% | -26.45% | -32.48% | -62.5% | 81% | - |
| EPS (Basic) | - | -7.26 | -9.27 | -12.34 | 21.26 | 30.31 | -1.96 | -1.55 | -1.17 | -0.72 | -3.79 |
| Diluted Shares Outstanding | 430M | 389M | 384M | 382M | 416M | 431M | 381.33M | 330.8M | 328.8M | 376M | 64.09M |
| Basic Shares Outstanding | 401M | 389M | 384M | 382M | 394M | 403M | 381.33M | 330.8M | 328.8M | 376M | 64.09M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying MRNA stock.
For fiscal year 2025, Moderna, Inc. (MRNA) reported total revenue of $1.94B. This represents a 1693.4% increase compared to $108.4M in 2016.
Moderna, Inc. (MRNA) reported a net loss of $2.82B for the fiscal year ending 2025.
Moderna, Inc. (MRNA) reported an operating income of $-3074.0M, resulting in an operating profit margin of -158.1%. This margin reflects the operational efficiency of the business before interest and taxes.
Moderna, Inc. (MRNA) generated $1.08B in gross profit for the year, representing a gross profit margin of 55.3%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Revenue concentration and commercial execution
Metrics are mathematically derived from official filings.
Quarterly Rebound Masks Trailing Revenue Decline
Based on the reported quarterly income statements, Moderna's Q3 2026 revenue of $1.3B represented 29.2% year-over-year growth, but trailing-twelve-month revenue remains down 39.2%, indicating the rebound has not yet offset the post-pandemic contraction.
The jump from $145.0M in Q2 2026 to $1.3B in Q3 2026 reflects the seasonal concentration of respiratory vaccine sales in the second half of the calendar year, which makes a single quarter a weak basis for judging durability. The reported figures suggest the company's top line is still resetting toward a smaller commercial demand base, so investors should monitor whether Q4 2026 sustains a comparable level of revenue rather than extrapolating one seasonal peak.
Gross Margin Swings Reflect Volume Dependence
As reported in the quarterly income statements, Moderna's gross margin ranged from 15.9% to 75.8% across recent quarters, with the Q3 2026 peak of 75.8% contrasting sharply with the 33.3% and 35.9% seen in adjacent periods.
Such wide swings suggest gross profit is driven more by the timing of high-volume shipments and milestone or collaboration revenue than by a stable unit-economics baseline. Underutilized manufacturing capacity appears to be weighing on cost absorption in weaker quarters, which may indicate that structural margins depend on sustained demand recovery. Investors should treat the Q3 2026 margin as a potentially non-recurring high point until it is confirmed across multiple periods.
Operating Losses Persist Despite Cost Discipline
Based on reported figures, Moderna's R&D spending remained above $580M in every recent quarter, while the operating margin still reached -158.1% on a trailing basis, implying fixed research and infrastructure costs continue to outpace gross profit.
R&D and SG&A together absorbed far more than gross profit in most periods, meaning operating income has been dominated by the size of the fixed cost base rather than by revenue scaling. The reported figures do not yet show operating income scaling faster than gross profit in a sustained way, which warrants further investigation into how quickly the cost base can adjust to lower pandemic-era volumes.
Q3 EPS Beat Requires Scrutiny
According to the reported Q3 2026 figures, Moderna's diluted EPS of $0.38 contrasted with a prior-quarter loss of $1.96 per share, but net income of $162.0M on $1.3B revenue implies a net margin of 12.3%, a level the company has not sustained in the period shown.
A swing from deep losses to a profit in a single quarter suggests the result may include one-time or timing-related items rather than purely recurring operating earnings. Stock-based compensation of $127.0M in the quarter remains a meaningful cost that the headline EPS may not fully reflect in its underlying trend. Investors should verify the composition of Q3 net income before treating the beat as evidence of a durable earnings inflection.
Sustained Losses Challenge the Inflection Thesis
Based on reported figures, Moderna's net margin of -145.2% on a trailing basis and cumulative quarterly losses exceeding $800M in several periods suggest the Q3 2026 profit may prove an isolated seasonal event rather than the start of sustained profitability.
The bear case centers on the fact that the company has posted losses in the large majority of quarters shown, and that a single profitable quarter does not offset the trailing deficit. If commercial market share erodes against entrenched incumbents, the high fixed-cost base could keep operating margins deeply negative. Investors should monitor whether subsequent quarters confirm the Q3 result or revert to the pattern of large operating losses.